
    
      Before the approval of BESPONSA® in Korea, this non-interventional study is designated as a
      Post-Marketing Surveillance (PMS) Study and is a commitment to Ministry of Food and Drug
      Safety (MFDS), as a part of Risk Management Plan (RMP) which is required by MFDS. The safety
      and effectiveness information of BESPONSA® will be gathered at minimum 160 subjects
      administered in the setting of routine practice in Korea during the initial 6 years after the
      approval.
    
  